Torrey Pines Law Group's founder, Kevin Buckley, has been a biotech patent attorney for more than 20 years. Prior to becoming a patent attorney, Kevin was a biochemist for many years at UC San Diego as well as in industry on the Torrey Pines mesa where he studied immuno-oncology, RNA-derived therapeutics, and bioinformatics systems.
His experience has provided both his clients and his colleagues valuable insight into solving complex legal problems related to:
Torrey Pines Law Group's clients are on the leading edge of biotechnology innovation. Those biotechnology innovations include technologies that affect our daily lives such as personalized medicine, biosensors, and diagnostics. Kevin has also helped advance more controversial technologies including "pharming," regenerative medicine, embryonic stem cell research, pluripotent stem cells, and gene editing.
One can imagine that the entire body of biotechnology law that affects this patchwork of technologies is as varied and far-reaching as the underlying technologies themselves. Biotechnology law has become a continuously adaptive body of law that evolves with the pace of biotechnology development, and because biotechnology law is also influenced by business cycles and the market, the most effective way to understand biotechnology law is by studying its evolution at the intersection of law, business, and science. Legal issues at this intersection include intellectual property (especially patents), federal regulation, research funding, federal approval of products for human use, privacy issues, and international issues, among many other unique legal issues.
The IP attorneys, patent lawyers, engineers, scientists, and patent agents at Torrey Pines Law Group have also worked in a variety of biotechnology industries and have assisted with commercializing, researching, and developing technologies including:
Torrey Pines Law Group, PC serves technology innovators with protecting intellectual property, obtaining regulatory approvals and clearances, and making deals and closing technology transactions throughout the U.S., including in major technology hubs such as San Diego, San Francisco, Palo Alto, San Jose, Silicon Valley, Boston, Cambridge, Chicago, Minneapolis, Houston, Dallas, Atlanta, Denver, Seattle, Portland, Boulder, Orlando, the Research Triangle (Raleigh, Durham, and Chapel Hill), the Mid-Atlantic (New Jersey, New York, Philadelphia, Maryland, Virginia, and Washington, DC), Pittsburgh, Cleveland, Ann Arbor, and throughout Southern California in Los Angeles, Orange County, Irvine, Torrey Pines, Sorrento Valley, and La Jolla.
We have experience with international intellectual property, regulatory and transactional matters pending in Beijing, Shanghai, Shenzhen, and Guangzhou China; Tokyo, Japan; Berlin, Munich and Frankfurt Germany; Tel Aviv Israel; Mumbai, Bengaluru, and New Delhi India; London and Edinburgh United Kingdom; Vancouver, Toronto, Calgary and Montreal Canada; Dublin, Ireland; Cape Town, South Africa; Mexico City and Tijuana Mexico; Brussels, Belgium; Copenhagen, Denmark; Paris, France; Madrid and Barcelona Spain; Moscow, Russia; Santiago, Chile; Montevideo, Uruguay; Buenos Aires, Argentina; Sao Paulo and Rio de Janeiro Brazil; Seoul, South Korea; Taipei, Taiwan; Hong Kong; Hanoi, Vietnam; Bangkok, Thailand; Kuala Lumpur, Malaysia; Milan, Italy; Singapore; Sydney, Melbourne, Perth and Adelaide Australia; Auckland, New Zealand; Oslo, Norway; Stockholm, Sweden; Helsinki, Finland; Kiev, Ukraine; Budapest, Hungary; Vienna, Austria; Prague, Czechia; Geneva and Lausanne Switzerland; Bahrain; Doha, Qatar; Abu Dhabi and Dubai UAE; and Jeddah, Saudi Arabia.
Biotechnology Patent Attorneys - Biopharmaceutical Patent Preparation & Prosecution Lawyers - Biotech Intellectual Property Law Firm - Monoclonal Antibody and Nanobody IP - RNAi Lawyers - Vaccine Counsel - CRISPR law